RxDoctor Payments Data

Charles McMahon, MD

Ophthalmology · Colorado Springs, CONPI 1639168735

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $46,052 of the $46,688 with a category attached, or 98.6%. Optos, Inc. accounts for 98.6% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $46,090, more than ten times the $288 reported in 2019. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$46,688in general payments, 2019–2025

Across 19 payments — averaging $2457.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optos, Inc.$46K
  • Aerie Pharmaceuticals, Inc.$290
  • Hoffmann-la Roche Limited$140
  • Thea Pharma Inc.$76
  • AbbVie$44
  • Lumibird Medical Inc.$29
  • plus $57 from 3 others

What the payments were for

  • Speaking & faculty fees$46,05299%
  • Food & beverage$6361%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,688 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$68,256
Medicare patients
156
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost34$19,220
RocklatanNetarsudil Mesylat/Latanoprost22$11,817
Prednisolone Acetate36$2,223
Brimonidine Tartrate215$1,594
Pilocarpine Hcl12$804
Dorzolamide Hcl35$604
Latanoprost69$497
Gabapentin17$78
Prednisone15$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$44$19,22034 claims
Aerie Pharmaceuticals, Inc.Rocklatan$290$11,81722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →